CanWell Pharma will update company’s ADC programs at ADC & Novel Conjugates Partnering & Investment Summit held on September 9-10, 2025 in Boston. It covers newest research updates on StarLinker dual/tri-payload ADCs, which had been making tremendous progress in preclinical efficacy studies overcoming tumor heterogeneity and drug resistance, while maintaining excellent tolerability in preclinical safety studies.
Date: September 9-10, 2025
Location: Hyatt Regency Boston, One Avenue de Lafayette, Boston, MA 02111, United States